|1.||Panasci, L C: 3 articles (03/2001 - 10/2000)|
|2.||Carter, C A: 3 articles (03/2001 - 10/2000)|
|3.||Panasci, Lawrence: 2 articles (07/2006 - 12/2004)|
|4.||Huynh, Hung: 2 articles (07/2006 - 12/2004)|
|5.||Chen, Z: 2 articles (03/2001 - 10/2000)|
|6.||Alley, M C: 2 articles (03/2001 - 10/2000)|
|7.||Chen, Z P: 2 articles (03/2001 - 01/2001)|
|8.||Tran, Evelyn: 1 article (07/2006)|
|9.||Soo, Khee Chee: 1 article (07/2006)|
|10.||Chow, Pierce K H: 1 article (07/2006)|
01/01/2001 - "Our present results suggest that SarCNU is also effective for MGMT positive tumor if they exhibit EMT."
01/15/2003 - "SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors."
12/15/2004 - "Although 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU), an analog of the chloroethylnitrosoureas, has been used in the treatment of advanced solid tumors, the molecular mechanisms underlying the antineoplastic activity of this agent are not well understood. "
03/01/2001 - "The results suggest that expression of both EMT and DNA repair genes, specifically, MGMT, ERCC2 and ERCC4, are important determinants of SarCNU activity against human tumors. "
10/20/2000 - "The results suggest that anti-tumor effect of SarCNU in EMT positive tumor is satisfactory even though the tumor exhibits DNA repair gene expression,specifically MGMT and ERCC1-6."
12/01/2005 - "Despite promising preclinical data, SarCNU caused pulmonary toxicity in patients with recurrent malignant glioma and we plan no further studies in this indication."
12/01/2005 - "Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group."
09/15/1997 - "These results encourage the initiation of clinical trials for SarCNU, in an effort to improve therapeutic approaches to glioma, but clinical trials must determine whether superiority of SarCNU in preclinical models can be extrapolated to patients."
01/15/2003 - "SarCNU demonstrates selective cytotoxicity in vitro against human glioma at least in part because of the selective SarCNU uptake by the extraneuronal monoamine transporter. "
01/15/2003 - "2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) is a novel chloroethylnitrosourea that demonstrates selective cytotoxicity in athymic mice bearing human glioma. "
|3.||Hepatocellular Carcinoma (Hepatoma)
09/01/2005 - "In the present study, we report that in vitro treatment of primary hepatoma, HepG2 (wild-type p53), PLC/PRF/5 (p53-mutant), and Hep3B (p53-deleted) cells with 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) resulted in upregulation of p53, p21(Cip1/Waf1), phosphorylated cdc-2 at Tyr15 in wild-type p53 cells and phosphorylation of cdc-2 at Tyr15 in p53-mutant or p53-deleted hepatoma cells. "
09/01/2005 - "These findings indicate that SarCNU-induced G(2)/M growth arrest in hepatoma cells by a p53-independent phosphorylation of cdc-2. "
09/01/2005 - "SarCNU-induced G2/M arrest in hepatoma cells is mediated by a p53-independent phosphorylation of cdc-2 at Tyr15."
07/15/2006 - "Hepatocellular carcinoma xenografts are powerful tools for screening drugs and SarCNU may be useful in the treatment of this fatal disease."
|4.||Colorectal Neoplasms (Colorectal Cancer)
07/01/2006 - "SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group."
07/01/2006 - "Eighteen patients with recurrent or metastatic colorectal cancer following first-line chemotherapy were treated with SarCNU 860 mg/m2 orally day 1, 5 and 9 every 6 weeks. "
07/01/2006 - "To evaluate the activity and toxicity of SarCNU, an oral chloroethylnitrosourea in patients with recurrent or metastatic colorectal cancer who have progressed after first-line chemotherapy. "
12/15/2004 - "In the current study, the authors sought to investigate the effects of SarCNU on prostate carcinoma cell growth in vivo and in vitro. "
12/15/2004 - "SarCNU induced G2/M arrest in prostate carcinoma cells via p53-dependent up-regulation of p21Cip1/Waf1 and p53-independent phosphorylation of Cdc-2 at Tyr15. "
12/15/2004 - "2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways."
|4.||Catecholamine Plasma Membrane Transport Proteins
|7.||2'- (2- hydroxyphenyl)- 2'- thiazoline- 4'- carboxylic acid
|9.||lissamine rhodamine B (sulforhodamine B)
|1.||Heterologous Transplantation (Xenotransplantation)